This analysis examined type 2 diabetes (T2D) as a predictor of colorectal cancer (CRC) survival within the Multiethnic Cohort Study. Registry linkages in Hawaii and California identified 5,284 incident CRC cases. After exclusion of cases with preexisting cancer diagnosis within 1 year and systemic disease, the analytic dataset had 3,913 cases with 1,800 all-cause and 678 CRC-specific deaths after a mean follow-up of 9.3 6 5.2 years. Among CRC cases, 707 were diagnosed with T2D 8.9 6 5.3 years before CRC. Cox regression with age as time metric was applied to estimate hazard ratios (HR) and 95% confidence intervals (CI) for T2D status as predictor of CRC-specific and all-cause survival while adjusting for known confounders. Overall, CRC-specific survival was not associated with pre-existing T2D (HR 5 0.84; 95% CI 5 0.67-1.07). However, a significant interaction was seen for comorbidity (p interaction 5 0.03) with better survival among those without pre-existing conditions (HR 5 0.49; 95% CI 5 0.25-0.96) while no association was seen in patients with comorbid conditions. All-cause mortality was also not related to pre-existing T2D (HR 5 1.11; 95% CI 5 0.98-1.27), but significantly elevated for individuals with T2D reporting comorbid conditions (HR 5 1.36; 95% CI 5 1.19-1.56). Stratification by T2D duration suggested higher CRC-specific and all-cause mortality among participants with a T2D history of 10 than <10 years. The findings were consistent across sex and ethnic subgroups. In contrast to previous reports, pre-existing T2D had no influence on disease-specific and all-cause survival among CRC patients. Only participants with additional comorbidity and possibly those with long T2D duration experienced higher mortality related to T2D.
As the aging of the population continues worldwide, the number of people living with two chronic diseases, such as colorectal cancer (CRC) and type 2 diabetes (T2D), is increasing. 1 CRC is the fourth most commonly diagnosed malignancy in the U.S. with an estimate of about 135,000 new cases and 50,000 deaths per year. 2 At the same time, the epidemic of T2D is expected to grow to 642 million people worldwide by 2040. 3 The two chronic diseases have many risk factors in common including older age, low-quality diet, obesity, physical inactivity and smoking. 4 There is evidence that a T2D diagnosis may be associated with an increased cancer risk and worse prognosis. 5 For example, T2D is associated with an 30% higher risk to develop CRC in some populations. [6] [7] [8] As to the influence of T2D on survival among CRC patients, findings are inconsistent and the number of reports is relatively small. A T2D diagnosis was associated with higher CRC-related mortality in five studies, 1, [9] [10] [11] [12] but several investigations reported no significant association [13] [14] [15] or a higher mortality from cardiovascular disease only. 16 Many predictors of survival among CRC patients have been identified; these may assist patients and healthcare personnel in decision making and disease management. 12 However, few previous studies have looked at the influence of T2D status in different ethnic groups. Given the high T2D incidence in many non-white populations 17 and the elevated CRC incidence in Japanese and African Americans, 18 it is of interest to identify ethnic-specific differences in the association to understand differences in prognosis. This study investigates the hypothesis that a diagnosis of T2D shortens survival among white, African American, Japanese American, Native Hawaiian and Latino participants of the Multiethnic Cohort (MEC) with CRC.
Methods

Study population
In (Figure 1 ).
Questionnaire and diabetes data
At baseline, all participants completed a 26-page, self-administered mail questionnaire (QX1) asking for demographic information, a lifetime smoking history, dietary history assessed by a validated food frequency questionnaire, 20 and physical activity during the last year. 19 As partial validation, the association of sleep duration with objective measures of energy balance was demonstrated in a subset of cohort members. 21 In and hospital discharge diagnosis data in California. 24 Considering records from all 3 data sources, 83% of T2D selfreports were confirmed by at least one administrative data source. Participants with unconfirmed self-reports were considered individuals without a T2D diagnosis.
Statistical analysis
We compared participants with and without T2D for major characteristics. To evaluate the association of T2D with overall and CRC-specific mortality, we computed multivariableadjusted hazard ratios (HRs) and 95% confidence intervals (CI) using Cox proportional hazards models. To minimize bias due to the inclusion of incident T2D cases after CRC diagnosis (N 5 39; 5.2%), only T2D cases detected before CRC diagnosis (N 5 707) were included in the models. With age as the time metric, the follow-up time started at the age at CRC diagnosis and ended at the age of death or the end of follow-up on December 31, 2013. For CRC-specific death analysis, participants who died of other causes were censored at the time of death. All analyses were adjusted for age, ethnicity, education, physical activity (<30 vs. 30 min of daily moderate/vigorous activity), smoking status, use of nonsteroidal anti-inflammatory drugs (NSAID), family history of CRC, comorbidity (heart attack or stroke) at cohort entry and BMI as time-varying variable from QX1 and QX2. The covariate selection was based on previous cancer survival analyses within the MEC. 23, 25 For covariates with missing values, that is, physical activity, smoking status, family history of CRC and comorbidity, a missing category was created. To evaluate T2D duration, the time between first-known T2D and CRC diagnosis was divided into <10 and 10 years. All analyses were stratified by T2D duration, sex, ethnicity, tumor site, stage of disease, family history of CRC and comorbidity.
Interactions were assessed using a global Wald test of the cross-product terms. All analyses were conducted in SAS 9.4 (SAS Institute Inc., Cary, NC) using two-tailed tests with significance set at p < 0.05.
What's new?
Previous studies evaluated the influence of type 2 diabetes (T2D) on the prognosis of colorectal cancer patients, but studies from populations with diverse ethnic groups are rare. Here the authors performed a Multiethnic Cohort study in California and Hawaii and found no association between T2D and colorectal cancer-specific and all-cause survival except in participants with other comorbid conditions or long T2D duration. Ethnic differences were minimal except for Latinos, where a T2D history predicted worse all-cause survival, possibly underscoring disparities in health care access and utilization.
Results
Among 3,913 CRC cases (Table 1) , 707 (18.1%) had known T2D before being diagnosed with CRC. The respective mean ages of participants at cohort entry, T2D discovery, CRC diagnosis and survival (age at death or 12/31/2013) were 62.6, 68.6, 72.5 and 79.7 years, respectively. The mean follow-up time from CRC diagnosis was 9.3 6 5.2 years. T2D was diagnosed 10 years before CRC in 284 participants and <10 years among 423 cohort members. The mean time between T2D detection and CRC diagnosis was 8.9 6 5.3 years. Pre-existing T2D rates across stage at diagnosis and tumor grade were not substantially different. Japanese Americans represented the largest proportion of the study population, followed by Latinos, African Americans, whites and Native Hawaiians. Whites had the lowest rate of T2D (11%), with higher rates among Japanese Americans (17%), Native Hawaiians (18%), African Americans (20%) and Latinos (25%). Native Hawaiians had the highest proportion of overweight and obese participants (89%) with lower rates among African Americans (76%), Latinos (74%), whites (62%) and Japanese Americans (44%). Stage of disease at diagnosis also differed by ethnicity. Latinos had the highest percentage of regional disease (46%) followed by Japanese American (44%), whites (42%), African Americans (40%) and Native Hawaiians (38%).
In total, 1,800 all-cause and 678 CRC-specific deaths were recorded. CRC-specific survival (Table 2) was not related to a T2D diagnosis (HR 5 0.84; 95% CI 5 0.67-1.07) in the entire study population, but the association differed according to comorbidity status (p interaction 50.03). A history of T2D versus no T2D predicted lower mortality in those without additional pre-existing conditions (HR 5 0.49; 95% CI 5 0.25-0.96); however, no association was seen in patients with comorbid conditions. Stratification by duration of known T2D also suggested differences. The association of T2D <10 years with CRC-specific mortality was inverse (HR 5 0.61; 95% CI 5 0.46-0.82), whereas T2D for 10 years predicted a higher mortality (HR 5 1.48; 95% CI 5 1.06-2.07). The interaction terms for sex, ethnicity, stage at diagnosis, tumor site and family history of CRC were not significant in the CRCspecific models despite small differences in risk estimates.
T2D status was also not associated with overall all-cause mortality (Table 3) , but in participants with pre-existing comorbidity, T2D was related to 36% higher mortality (95% CI 5 1.19-1.56; p interaction 50.03). Also, in cases with rectal but not colon cancer, T2D predicted a higher mortality (HR 5 1.33; 95% CI 5 1.03-1.78). The significant interaction with ethnicity (p interaction 50.04) was likely due to the 62% higher T2D-related mortality among Latinos (95% CI 5 1.24-2.11). All-cause mortality also appeared elevated for those with 10 years of T2D (HR 5 1.49; 95% CI 5 1.22-1.82) but not in those with shorter T2D duration. No significant interactions by sex, stage at diagnosis and family history were detected.
Adjustment for stage and treatment-that is, radiotherapy and chemotherapy-did not substantially affect the results of the models. The respective HRs were 0.85 (95% CI 5 0.67-1.07) for CRC-specific mortality and 1.12 (95% CI 5 0.98-1.27) for all-cause mortality.
Discussion
This study within a large population-based cohort of five ethnic groups detected no association of T2D before a CRC diagnosis with disease-specific and all-cause survival. However, among individuals with self-reports of additional comorbidity, those with T2D experienced lower survival than those without T2D. It also appeared that a longer known T2D duration predicted worse survival than the presence of T2D for <10 years, but caution is necessary as the exact time of T2D diagnosis was not known. The relation was consistent across subgroups defined by sex, tumor site (except for all-cause mortality) and family history of CRC. Ethnic differences in the association between T2D and mortality were minimal; a T2D history predicted worse all-cause survival among Latinos.
The current null results are in contrast to many publications reporting substantially lower survival for CRC patients with 
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T2D than for those without. A large study with 500,000 CRC cases within the British health care system reported a 12-14% higher CRC-specific and a 23-24% higher all-cause mortality even after controlling for a large number of prognostic factors. 12 A higher cancer-specific mortality was detected for men with T2D independent of T2D medication in a Danish registry-based analysis. 10 For all-cause mortality, the majority of studies reported a 20-30% higher mortality for CRC patients with T2D than without T2D. 9 Whereas one study detected higher overall mortality for patients with T2D compared to those without for colon (HR 5 1.28; 95% CI 5 1.14-1.42) and rectum (HR 5 1.48; 95% CI 5 1.28-1.73), 1 a Scottish report described higher all-cause mortality for colon but not rectal cancer. 16 In a retrospective study of SEER and Medicare data, 11 a higher overall mortality was observed in colon cancer patients with elevated glucose/T2D across all stages (HR 5 1.17; 95% CI 5 1.13-1.21). On the other hand, several studies also reported null associations for T2D and all-cause mortality in CRC patients, for example, a retrospective cohort based on 350 UK primary care practices, 13 1,029 nonmetastatic CRC cases in China 15 and an analysis of 1,127 CRC cases.
14 Possible reasons for discrepant findings across studies include duration and severity of T2D; adverse effects of T2D on survival may depend on years of experiencing T2D as demonstrated by differential risk estimates according to duration in the current analysis. Alternatively, more frequent contact with health care personnel among patients with diagnosed T2D than those without T2D may encourage screening and early detection. A colonoscopy with removal of polyps and/or a change in lifestyle at an earlier stage of the disease may contribute to a slower progression of CRC. Different rates of undiagnosed T2D and impaired glucose tolerance (IGT), which is highly prevalent in some populations, 26 may influence the results. 27 Finally, the type of T2D medication used within a study population may affect survival. Metformin use predicted better all-cause survival than other T2D medications in several reports, [28] [29] [30] but medication data in the MEC are limited to QX3 participants. The small ethnic differences in the current analysis may be due to health care access and utilization. For example, CRC screening rates as reported by the Behavioral Risk Factor Survey System 31 were higher in Japanese Americans (75%) than in whites (69%) and Native Hawaiians (59%) in Hawaii and higher for whites (61%) than African Americans (59%) and Latinos (38%) in California. This behavior may explain the lower proportion of regional stage disease and the higher all-cause mortality among Latinos.
Strengths of this study include the longitudinal study design allowing data to be collected over 24 years and the large number of ethnically diverse cases with relatively similar access to health care. Limitations include the lack of detailed information about treatment, especially beyond the first course of cancer treatment, and the exact time of T2D diagnosis. The known T2D duration used for the current analysis may be biased by age at cohort entry, questionnaire participation, and availability of claims data. As no glucose measurements were obtained in cohort members, possible undiagnosed T2D and IGT may have caused exposure misclassification and biased the association toward the null. Other limitations include the small sample sizes in some ethnic groups, the lack of information on colonoscopy screening and the possibility of behavioral changes after being diagnosed with CRC or T2D.
In this large multiethnic population with overall null findings, CRC patients with T2D and other chronic conditions, such as heart disease or stroke, experienced worse survival than those without T2D. Also, a long history of T2D predicted lower survival. Disparate survival among CRC patients with T2D across populations may be the result of screening practices, lifestyle behavior and treatment. Based on the current data, CRC patients may not experience higher mortality despite a preexisting T2D as long as they are in good cardiovascular health.
